Montana bill would bar retroactive denials, set standards for off‑label biologic use in minors

Representative Ed Buttrell introduced House Bill 544 in the House Business and Labor Committee, saying the bill would stop most retroactive denials by insurers and set standards for when insurers may require prior authorization for biologic therapies used in minors.

The bill disallows retroactive denials except in the case of fraud, misrepresentation, nonpayment of premium or exhaustion of benefits. It also requires that off‑label use of biologic therapies for minors be supported by medical literature in at least two peer‑reviewed journals and that insurers respond to properly documented prior‑authorization requests within the timelines already established in Title 33, chapter 32 of Montana law. Section 3 would extend similar requirements to the State Employees’ Group Benefits Plan and the Montana University System group benefits plan.

Why it matters: Doctors and family members said the current prior‑authorization and retroactive‑denial practices can delay life‑saving treatments and impose large, unanticipated costs on families. Several speakers said the most urgent cases involve children with very early onset inflammatory and autoimmune conditions for whom biologics—often not labeled by the Food and Drug Administration (FDA) for young patients—can be the difference between outpatient treatment and repeated hospitalizations.

Clinicians, parents and advocates described lengthy appeals and delayed approvals. ‘‘There is a rigorous process to go through to get FDA approval,’’ said Kim Longcake, an advanced nurse practitioner who specializes in pediatric gastroenterology, and added that manufacturers often do not seek pediatric labeling because of small patient numbers. She told the committee she has ‘‘horror stories for days’’ about patients who waited months for approvals and were repeatedly hospitalized in the interim.

Parents described the financial and emotional stakes. Rachel Markovich, who testified as a mother and founder of the nonprofit VEO Guardians, said her son was prescribed a biologic in 2022 and the family faced months of denials and delays while his condition worsened; she said the medication cost roughly $5,000 per dose and charity is not a sustainable substitute for insurance coverage.

Medical groups including the Montana Medical Association, the Montana Hospital Association and the Montana chapter of the American Academy of Pediatrics testified in support. Attorneys and drafters who assisted the bill told the committee they negotiated the language with payers and other stakeholders to narrow the exceptions and address payer concerns.

No committee vote or formal action was recorded in the transcript excerpt.

The hearing record: proponents urged passage and told personal stories about delays and retroactive denials; there were no opponents or informational witnesses listed in the hearing record provided. Representative Buttrell closed by asking the committee to advance the bill; the hearing ended with the chair closing the record on House Bill 544.